The National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block – G
Bandra – Kurla Complex
Bandra (East)
Mumbai – 400 051

6th April, 2015

Sub: Disclosures under Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir,

We, the undersigned as Promoters of Marksans Pharma Limited, hereby enclose disclosures of our shareholding in Marksans Pharma Limited as on 31st March, 2015 pursuant to the Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Thanking You.

Yours faithfully,

(Mark Saldanha) (Sandra Saldanha)

Enclosed as above.

CC.: Marksans Pharma Limited
11th Floor, Grandeur
Veera Desai Extension Road
Oshiwara, Andheri (W), Mumbai – 400053

Disclosures under Regulation 30(1) & 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

PART – A – Details of Shareholding

1	Name of the Target Company (TC)	MARKSANS PHARMA LIMITED		
2	Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. The National Stock Exchange of India Limited. 2. BSE Limited		
3	Particulars of the shareholder(s) :			
a	Name of Person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. OR	-		
b	Name(s) of promoter(s), member of the promoter group and PAC with him	1. Mr. Mark Saldanha 2. Mrs. Sandra Saldanha		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share/ voting capital wherever applicable	% of total diluted share/ voting capital of TC (*)
	As of 31 March, 2015, holding of :			
	a) Shares	197491733	48.25	48.24
	b) Voting rights (otherwise than by shares)	-	-	-
	c) Warrants	-	-	-
	d) Convertible Securities	-	-	-
	e) Any other instrument that would entitle the holder to receive shares in the TC	-	-	-
	Total	197491733	48.25	48.24

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC. It includes 81,314 equity shares that might be issued in case conversion right is exercised by all the holders of outstanding Foreign Currency Convertible Bonds of the TC.

(**) Marksans Pharma Limited has issued and allotted 2,40,06,494 Equity Shares of Re. 1/- each face value to qualified institutional buyers under QIP on 30th March, 2015. Accordingly, the Company's Issued and Paid-up Equity Share Capital has increased to 40,93,13,698 Equity Shares of Re. 1/- each face value with effect from 30th March, 2015.